Atherogenesis: why women live longer than men
- PMID: 3965355
Atherogenesis: why women live longer than men
Abstract
The total LDL:HDL cholesterol ratio, at higher levels, appears sufficient to account for the risk of clinical atherosclerosis in both sexes. At lower levels, however, women continue to enjoy less risk of atherosclerosis even at LDL:HDL cholesterol ratios equivalent to those in men. Median LDL levels are higher in men than in women until the menopause, beyond which a crossover occurs, and median levels become higher in women. However, though the difference narrows in the post-menopausal years, the LDL:HDL ratio is never higher in women than in men.
PIP: This article addresses the question of why women seem to be more protected than men from the consequences of premature atherosclerosis. At higher levels, the total low density lipoprotein (LDL): high density lipoprotein (HDL) cholesterol ratio seems to account for the risk of atherosclerosis in both sexes. However, at lower levels, women appear to be at less risk of atherosclerosis than men even when LDL: HDL cholesterol ratios are equivalent. The median LDL level is greater in males from puberty until menopause, and greater in females after menopause. Although gender differences narrow in the postmenopausal period, the LDL: HDL ratio is always higher in men. Thus, it is hypothesized that the sex differential in the secretion of sex hormones accounts for the sex differential in lipoproteins, which in turn explains the sex differential in atherogenic risk and produces sex differences in relative longevity. Consistently lower levels of LDL and higher levels of HDL cholesterol have been noted among women taking exogenous estrogens for postmenopausal replacement compared with women not taking hormones. Studies of various combinations of oral contraceptives have indicated that the strength of the progestin component compared to that of estrogen determines whether HDL levels are higher, the same, or lower than in women not taking these preparations. In contrast, the administration of androgenic substances to postmenopausal women is associated with increases in LDL cholesterol and decreases in HDL cholesterol.
Similar articles
-
Women, lipoproteins and cardiovascular disease risk.Can J Cardiol. 1990 May;6 Suppl B:23B-29B. Can J Cardiol. 1990. PMID: 2188715 Review.
-
[Women and ischemic cardiopathy].Rev Clin Esp. 1989 Oct;185(6):308-15. Rev Clin Esp. 1989. PMID: 2695994 Review. Spanish.
-
Metabolic profile of six oral contraceptives containing norgestimate, gestodene, and desogestrel.Int J Fertil Menopausal Stud. 1995;40 Suppl 2:98-104. Int J Fertil Menopausal Stud. 1995. PMID: 8574257 Clinical Trial.
-
The prevalence of hyperlipidemia in women and its association with use of oral contraceptives, sex hormone replacement therapy and nonlipid coronary artery disease risk factors. Canadian Heart Health Surveys Research Group.Can J Cardiol. 1999 Apr;15(4):419-27. Can J Cardiol. 1999. PMID: 10322251
-
Changes in lipoproteins with various sex steroids.Obstet Gynecol Clin North Am. 1987 Mar;14(1):107-19. Obstet Gynecol Clin North Am. 1987. PMID: 3306515 Review.
Cited by
-
A woman's heart. An update of coronary artery disease risk in women.West J Med. 1988 Dec;149(6):751-7. West J Med. 1988. PMID: 3074576 Free PMC article. Review.
-
Longitudinal associations between objective sleep and lipids: the CARDIA study.Sleep. 2013 Nov 1;36(11):1587-95. doi: 10.5665/sleep.3104. Sleep. 2013. PMID: 24179290 Free PMC article.
-
Burden of Hyperlipidemia, Cardiovascular Mortality, and COVID-19: A Retrospective-Cohort Analysis of US Data.J Am Heart Assoc. 2025 Mar 4;14(5):e037381. doi: 10.1161/JAHA.124.037381. Epub 2025 Feb 27. J Am Heart Assoc. 2025. PMID: 39526321 Free PMC article.
-
Loss of sex difference in high-density lipoprotein cholesterol in diabetic women during acute stress.J Clin Endocrinol Metab. 2014 Nov;99(11):E2357-61. doi: 10.1210/jc.2014-2466. Epub 2014 Aug 20. J Clin Endocrinol Metab. 2014. PMID: 25140403 Free PMC article.
-
Proteomic profiling reveals a higher presence of glycolytic enzymes in human atherosclerotic lesions with unfavourable histological characteristics.Cardiovasc Res. 2025 Jul 31;121(8):1187-1203. doi: 10.1093/cvr/cvaf077. Cardiovasc Res. 2025. PMID: 40354194 Free PMC article.